Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen
268535-76-8BeschreibungCetus has introduced a stable rDNA interleukin-2 (rIL-2) for the treatment of renal cell carcinoma. Recent studies showed that rIL-2 in combination with lymphokine activated killer cells or tumor infiltrating lymphocytes induced regression or partial regression in patients with advanced metastatic cancers.
DefinitionA type of biological response modifier (a substance that can improve the body’s natural response to disease). It stimulates the growth of certain disease-fighting blood cells in the immune system. Also called IL-2.